Clinical Trials Directory

Trials / Recruiting

RecruitingNCT05613049

Confounding Factors of Chronic Endometritis in Women With Reproductive Failure

Status
Recruiting
Phase
Study type
Observational
Enrollment
720 (estimated)
Sponsor
Chinese University of Hong Kong · Academic / Other
Sex
Female
Age
20 Years – 45 Years
Healthy volunteers
Not accepted

Summary

The aim of the study is to investigate the confounding factors of chronic endometritis and therapeutic benefits of antibodies targeting plasma cells in women with reproductive failure.

Detailed description

Eligible women, based on the inclusion and exclusion criteria, will be recruited from the IVF and/ or miscarriage clinic in the Prince of Wales Hospital/ CUHK medical centre (CUMC). Endometrial sampling (ES) will alternatively be conducted during mid-luteal phase. In natural cycles, all the subjects will have a daily urine test from day 9 of the menstrual cycle to identify the Luteinizing Hormone (LH) surge. The ES will be obtained precisely 7 days after LH surge. In artificial cycles, 6mg estradiol will be given daily orally from day 2 of the menstrual cycle for 14+/-1-2 days. Transvaginal ultrasound will be performed on day 14 of the estrogen therapy to assess the endometrial thickness and to exclude ovarian activity. If endometrial thickness is ≥8 mm, plasma progesterone level is \< 4nmol/L, progesterone will be commenced using either Endometrin (Ferring, Saint-Prex, Switzerland) 100 mg TDS vaginally. ES will be obtained using a Pipelle sampler as an outpatient procedure. The ES will be obtained precisely 5 days after progesterone supplementation. Immunohistochemical staining will be used to determine plasma cells by using a mouse antihuman monoclonal primary anti-CD138 antibody and anti-CD38 antibody. The total number of plasma cell present in the stroma of the entire specimen will be determined and expressed as plasma cell count per unit area of the specimen. If CE is present, antibiotics will be given following the guideline from the Hospital Authority (HA). Then ES will be taken again to be re-examined by histology and microbiology.

Conditions

Interventions

TypeNameDescription
OTHERIf the CE is high, antibiotics will be given to the patients as usual practice in hospitals.

Timeline

Start date
2023-01-26
Primary completion
2027-07-31
Completion
2028-01-31
First posted
2022-11-14
Last updated
2025-03-27

Locations

1 site across 1 country: Hong Kong

Source: ClinicalTrials.gov record NCT05613049. Inclusion in this directory is not an endorsement.